Synthetic Biologics Appoints VP Corporate Development
Synthetic Biologics Inc. has appointed Dr Isaac J. Bright vice president of corporate development. Bright brings over 15 years of transactional and operational experience to the clinical stage company, which focuses on developing therapeutics to protect the gut microbiome. Prior to joining Synthetic Biologics, Bright was a partner at US private equity investment practice Merieux Development, before which he was vice president, corporate development and diagnostics at QuantaLife Inc.
You may also be interested in...
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
US FDA will hold 10 December advisory committee on Pfizer/BioNTech's just-filed application; the WHO issued a recommendation against Gilead's Veklury for hospitalized patients.
Board directors appointed at Athersys, Trillium Therapeutics and Viatris